Bonesupport Holding AB Stock price

Equities

BONEX

SE0009858152

Pharmaceuticals

Delayed Nasdaq Stockholm 07:59:44 2024-03-28 am EDT 5-day change 1st Jan Change
228 SEK +0.88% Intraday chart for Bonesupport Holding AB +2.06% +21.15%
Sales 2023 591M 55.28M Sales 2024 * 857M 80.11M Capitalization 14.7B 1.37B
Net income 2023 245M 22.91M Net income 2024 * 128M 11.97M EV / Sales 2023 20.4 x
Net cash position 2023 167M 15.65M Net cash position 2024 * 257M 24.02M EV / Sales 2024 * 16.9 x
P/E ratio 2023
50.3 x
P/E ratio 2024 *
115 x
Employees 110
Yield 2023 *
-
Yield 2024 *
-
Free-Float 88.77%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.28%
1 week-0.45%
Current month+8.91%
1 month+8.59%
3 months+19.06%
6 months+76.93%
Current year+18.17%
More quotes
1 week
217.60
Extreme 217.6
235.80
1 month
191.70
Extreme 191.7
243.00
Current year
172.50
Extreme 172.5
243.00
1 year
79.40
Extreme 79.4
243.00
3 years
34.20
Extreme 34.2
243.00
5 years
19.05
Extreme 19.05
243.00
10 years
9.04
Extreme 9.04
243.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 18-02-28
Director of Finance/CFO 61 18-10-31
Chief Operating Officer - 21-11-30
Members of the board TitleAgeSince
Director/Board Member 66 -
Chairman 69 17-02-28
Director/Board Member 67 16-08-31
More insiders
Date Price Change Volume
24-03-28 228 +0.88% 84 229
24-03-27 226 -2.50% 186,215
24-03-26 231.8 +4.23% 188,905
24-03-25 222.4 +0.54% 87,948
24-03-22 221.2 -0.98% 109,916

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 05:46 am EDT

More quotes
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
226 SEK
Average target price
273.7 SEK
Spread / Average Target
+21.09%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Bonesupport Holding AB - Nasdaq Stockholm